1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 9, 8, 22, 4, 64, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Osteoporosis - Overview
- Osteoporosis - Therapeutics Development
- Osteoporosis - Therapeutics Assessment
- Osteoporosis - Companies Involved in Therapeutics Development
- Osteoporosis - Drug Profiles
- Osteoporosis - Dormant Projects
- Osteoporosis - Discontinued Products
- Osteoporosis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Osteoporosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Osteoporosis - Pipeline by Ablynx NV, H2 2020
- Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2020
- Osteoporosis - Pipeline by Addpharma Inc, H2 2020
- Osteoporosis - Pipeline by Aerami Therapeutics, H2 2020
- Osteoporosis - Pipeline by Affilogic SAS, H2 2020
- Osteoporosis - Pipeline by AgeX Therapeutics Inc, H2 2020
- Osteoporosis - Pipeline by AlphaMab Co Ltd, H2 2020
- Osteoporosis - Pipeline by Amgen Inc, H2 2020
- Osteoporosis - Pipeline by Angitia Biopharmaceuticals, H2 2020
- Osteoporosis - Pipeline by Aryogen Pharmed Co, H2 2020
- Osteoporosis - Pipeline by Axsome Therapeutics Inc, H2 2020
- Osteoporosis - Pipeline by Bainan Biotech ApS, H2 2020
- Osteoporosis - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
- Osteoporosis - Pipeline by BIOCND Inc, H2 2020
- Osteoporosis - Pipeline by Biosion Inc, H2 2020
- Osteoporosis - Pipeline by Bone Biologics Corp, H2 2020
- Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2020
- Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, H2 2020
- Osteoporosis - Dormant Projects, H2 2020
- Osteoporosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Osteoporosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ablynx NV
- Abreos Biosciences Inc
- Addpharma Inc
- Aerami Therapeutics
- Affilogic SAS
- AgeX Therapeutics Inc
- AlphaMab Co Ltd
- Amgen Inc
- Angitia Biopharmaceuticals
- Aryogen Pharmed Co
- Axsome Therapeutics Inc
- Bainan Biotech ApS
- Better Life Pharmaceuticals Inc
- BIOCND Inc
- Biosion Inc
- Bone Biologics Corp
- Bristol-Myers Squibb Co
- Cadila Healthcare Ltd
- Cellatoz Therapeutics Inc
- Celltrion Inc
- ChoDang Pharm Co Ltd
- Chugai Pharmaceutical Co Ltd
- Citragen Pharmaceuticals Inc
- Clayton Biotechnologies Inc
- Corium Inc
- CSPC Pharmaceutical Group Ltd
- Daewoong Pharmaceutical Co Ltd
- Dong Wha Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- Eli Lilly and Co
- EndoCeutics Inc
- Enesi Pharma Ltd
- Entera Bio Ltd
- Enteris BioPharma Inc
- Enzene Biosciences Ltd
- Enzo Biochem Inc
- Epygen Biotech Pvt Ltd
- Evgen Pharma Plc
- Galapagos NV
- Gbiologics Inc
- Genor BioPharma Co Ltd
- GlycoNex Inc
- GPN Therapeutics Inc
- Haoma Medica Ltd
- Helixmith Co Ltd
- Hengenix Biotech Inc
- Histide AG
- HNB Therapeutics LLC
- Hualan Biological Engineering Inc
- Huons Co Ltd
- Huons Global Co Ltd
- IMGENEX India Pvt Ltd
- Immunwork Inc
- InnoPharmaScreen Inc
- Innovent Biologics Inc
- InSight Biopharmaceuticals Ltd
- Intas Pharmaceuticals Ltd
- Ipsen SA
- JHL Biotech Inc
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Keros Therapeutics Inc
- Kolmar Pharma Co Ltd
- Kyoto Pharmaceutical Industries Ltd
- LBL Biotech Corp
- Lead Discovery Center GmbH
- Lupin Ltd
- Luye Pharma Group Ltd
- Max Biopharma Inc
- Merck & Co Inc
- Mesentech Inc
- Metabolab Inc
- Millendo Therapeutics Inc
- Nano Intelligent Biomedical Engineering Corp
- Nanomedic Inc
- NeuClone Pty Ltd
- NovMetaPharma Co Ltd
- Omeros Corp
- Oncosimis Biotech Pvt Ltd
- Ortho Regenics Pvt Ltd
- Paras Biopharmaceuticals Finland Oy
- PhytoHealth Corp
- Prestige BioPharma Pte Ltd
- Qilu Pharmaceutical Co Ltd
- R Pharm
- Regenerative Arthritis & Bone Medicine Inc
- Reliance Life Sciences Pvt Ltd
- Reven Pharmaceuticals Inc
- Ribomic Inc
- Sandoz International GmbH
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Biomabs Pharmaceuticals Co Ltd
- Shanghai Celgen Bio-Pharmaceutical Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shin Poong Pharm Co Ltd
- Stelis Biopharma Pvt Ltd
- Suzhou Stainwei Biotech Inc
- Taithera Inc
- Terpenoid Therapeutics Inc
- The National Institute for Biotechnology in the Negev Ltd
- Tritech Biopharmaceuticals Co Ltd
- TSH Biopharm Corporation Ltd
- Uni-Bio Science Group Ltd
- USV Pvt Ltd
- Vibe Pharmaceuticals LLC
- Vidasym Inc
- Viking Therapeutics Inc
- Yooyoung Pharm Co Ltd
- Zosano Pharma Corp
